FDA review process "robust", industry says
This article was originally published in Clinica
Executive Summary
As the scrutinising magnifying glass of the US Institute of Medicine (IOM) descends on the 510(k) procedure, the medical technology industry has insisted that the premarket notification process for devices offers “robust protection” for patients.